Author:
Allan-Blitz Lao-Tzu,Akbari Omid,Kojima Noah,Saavedra Edwyn,Chellamuthu Prithivi,Denny Nicholas,MacMullan Melanie A.,Hess Victoria,Shacreaw Maria,Brobeck Matthew,Turner Frederick,Slepnev Vladimir I.,Ibrayeva Albina,Klausner Jeffrey D.
Abstract
Abstract
Purpose
Long COVID is estimated to occur in 5–10% of individuals after acute SARS-CoV-2 infection. However, the pathophysiology driving the disease process is poorly understood.
Methods
We evaluated urine and plasma inflammatory and immune cytokine profiles in 33 individuals with long COVID compared to 33 who were asymptomatic and recovered, and 34 without prior infection.
Results
Mean urinary leukotriene E4 was significantly elevated among individuals with long COVID compared to asymptomatic and recovered individuals (mean difference 774.2 pg/mL; SD 335.7) and individuals without prior SARS-CoV-2 infection (mean difference 503.1 pg/ml; SD 467.7). Plasma chemokine ligand 6 levels were elevated among individuals with long COVID compared to individuals with no prior SARS-CoV-2 infection (mean difference 0.59 units; SD 0.42). We found no significant difference in angiotensin-converting enzyme 2 antibody levels. Plasma tumor necrosis factor receptor-associated factor 2 (TRAF2) levels were reduced among individuals with long COVID compared to individuals who were asymptomatic and recovered (mean difference = 0.6 units, SD 0.46). Similarly, the mean level of Sarcoma Homology 2-B adapter protein 3 was 3.3 units (SD 1.24) among individuals with long COVID, lower than 4.2 units (SD 1.1) among individuals with recovered, asymptomatic COVID.
Conclusion
Our findings suggest that further studies should be conducted to evaluate the role of leukotriene E4 as a potential biomarker for a diagnostic test. Furthermore, based on reductions in TRAF2, long COVID may be driven in part by impaired TRAF2-dependent immune-mediated inflammation and potentially immune exhaustion.
Publisher
Springer Science and Business Media LLC
Subject
General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference23 articles.
1. Subramanian A, Nirantharakumar K, Hughes S, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022 Aug;28(8):1706–1714.
2. World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus [Online]. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1. Accessed 6 Oct 2021
3. Arthur JM, Forrest JC, Boehme KW, et al. Development of ACE2 autoantibodies after SARS-CoV-2 infection. PLoS ONE. 2021;16(9): e0257016.
4. Doykov I, Hallqvist J, Gilmour KC, et al. ’The long tail of Covid-19’—The detection of a prolonged inflammatory response after a SARS-CoV-2 infection in asymptomatic and mildly affected patients. F1000Res. 2020;9:1349.
5. Sun B, Tang N, Peluso MJ, et al. Characterization and biomarker analyses of post-COVID-19 complications and neurological manifestations. Cells. 2021 Feb 13; 10(2):386
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献